ARA-290 10mg

• Lacks erythropoietic activity: Derived from erythropoietin (EPO), it provides tissue-protective benefits without stimulating red blood cell production or thickening the blood.
• Activates innate repair receptors: It selectively binds to the Innate Repair Receptor (IRR) complex, signaling cells to switch from a state of chronic injury to active tissue repair.
• Promotes small nerve regrowth: Clinical studies show it stimulates the regeneration of damaged unmyelinated small nerve fibers, making it a primary research target for small fiber neuropathy.
• Suppresses chronic neuroinflammation: It actively blocks pro-inflammatory cytokine pathways (such as TNF-α and IL-6) without suppressing the body's overall immune system function.
• Enhances local microvascular circulation: The peptide improves endothelial health and blood flow in restricted microvessels, accelerating healing in oxygen-deprived or highly stressed tissues. [

Mechanism: ARA-290 protects against hyperglycemia-induced neural damage, promotes nerve regeneration, and improves microvascular circulation to peripheral nerves.

Can ARA 290 treat neuropathy?

The small peptide ARA290, modeled from the 3-dimensional structure of EPO, has shown efficacy in preclinical models of disease, including neuropathy, without associated adverse effects.

Can Ara 290 treat diabetes?

ARA 290, a Nonerythropoietic Peptide Engineered from Erythropoietin, Improves Metabolic Control and Neuropathic Symptoms in Patients with Type 2 Diabetes.

FOR RESEARCH USE ONLY